In a 29-year-old patient who developed a well-demarcated raised plaque that subsequently formed a 3–4 cm tense bullae without any mucosal involvement, what is the most likely diagnosis and recommended treatment?

Bullous Pemphigoid, Not Erythema Multiforme

This clinical presentation—a 29-year-old with tense bullae (3-4 cm) arising from a demarcated raised plaque without mucosal involvement—is most consistent with bullous pemphigoid (BP), not erythema multiforme minor. While BP classically affects the elderly, it can occur in younger patients, and the key distinguishing features here are the tense (not flaccid) bullae and the urticarial/raised plaque prodrome 1.

Why This Is Bullous Pemphigoid

The clinical sequence you describe is pathognomonic for BP:

• Tense bullae: BP produces subepidermal blisters that are characteristically tense and filled with clear fluid, unlike the flaccid bullae of pemphigus or the targetoid lesions of erythema multiforme 2, 3
• Urticarial/raised plaque preceding blisters: Up to 20% of BP patients present with non-bullous manifestations first, including urticarial lesions, eczematous plaques, or infiltrated plaques before bullae develop 1
• Absence of mucosal involvement: BP typically spares mucosa (oral involvement is rare), which helps distinguish it from mucous membrane pemphigoid and pemphigus 1
• Severe pruritus: This is a hallmark feature that often precedes visible blistering 3, 4

Diagnostic Workup Required

You must confirm the diagnosis before initiating treatment:

1. Skin biopsy from an early blister on erythematous skin (place in formalin): Look for subepidermal blister with eosinophils and/or neutrophils 1

2. Direct immunofluorescence (DIF) from perilesional skin (NOT from the blister itself): This is the most critical test—you need linear IgG and/or C3 deposits along the dermoepidermal junction to confirm BP 1

3. Serology: Anti-BP180 and/or anti-BP230 IgG antibodies by ELISA provide additional confirmation 1

4. Obtain complete medication history: Ask specifically about diuretics and psycholeptic drugs taken in the past 1-6 months, as these can trigger BP 1

Treatment Algorithm

For Localized Disease (Single Body Site)

First-line: Topical clobetasol propionate 0.05% cream/ointment 10g daily applied to affected areas and surrounding skin 1. This is validated and preferred over systemic steroids due to lower mortality and fewer side effects.

For Extensive Disease (Multiple Body Sites)

If lesions involve multiple body regions:

• Topical clobetasol propionate 0.05%: 30-40g daily for extensive disease (validated, level 1 evidence) 1
• Alternative: Systemic prednisone 0.5-0.75 mg/kg/day if topical therapy is impractical, though this carries higher mortality risk than topical steroids in elderly patients 1

Do NOT use prednisone 1 mg/kg/day as initial therapy—this dosage is associated with increased mortality compared to topical steroids 1.

Treatment Duration and Monitoring

• Continue treatment until disease control (no new blisters, healing of existing lesions)
• After achieving control, begin tapering 15 days later 1
• Maintenance therapy: 10g clobetasol once weekly for 8 months (total 12 months including consolidation) 1
• If relapse occurs during taper: increase back to previous effective dose 1

Critical Pitfalls to Avoid

1. Don't dismiss BP because of young age: While uncommon in patients under 70, BP can occur in younger adults 5, 4

2. Don't wait for bullae to appear: Non-bullous presentations (urticarial plaques, eczema, prurigo) occur in 20% of cases and may precede blistering by weeks 1

3. Don't start treatment without DIF confirmation: The linear IgG/C3 deposits are essential for diagnosis and distinguish BP from other blistering disorders 1

4. Don't use high-dose systemic steroids as first-line: Topical clobetasol has superior safety profile with equivalent efficacy for extensive disease 1

5. Watch for steroid complications: In immunosuppressed patients on corticosteroids, be vigilant for opportunistic infections like oral candidiasis that can mimic disease progression 6

When to Refer

Given the complexity of diagnosis and management, refer to dermatology immediately for biopsy, DIF, and treatment supervision 1. BP has significant morbidity and mortality, particularly in elderly patients, and requires specialist oversight 1, 2.